GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Dorsomedial striatal GABA dynamics organize palatable reward consumption and are reshaped by GLP-1 receptor agonism

Design
Animal study · Unknown outcome
Match to healthy normal-weight adults aged 55–75
Not human evidence[Auto] Non-human (animal or cellular) evidence; no direct inference to any human population.
Could weight loss explain it?
Unknown[Auto] Non-human study; weight-loss mediation not assessable.
Study tier
Preliminary[Auto] Not peer reviewed (preprint, abstract or registration). Early-warning only.
Assessment
Version 1 · automatic, not yet reviewed by a person · Sep 20, 2026

Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75. This item has not been peer reviewed.

[Auto, unreviewed; last sentences of abstract] Optogenetic excitation of DMS GABAergic interneurons reproduced key semaglutide-induced changes in consumption structure. These findings suggest that DMS GABA dynamics, as a state-dependent regulator of palatable consumption, are reshaped by GLP-1 receptor agonism.

01Findings

What the study reported

Drugs
Semaglutide
Primary outcome
Not extracted
Effect
Not extracted
95% confidence interval
Not extracted
Follow-up
Not stated
Adverse events
Not extracted
Limitations
Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.

Who was studied

Study quality details

Study design
Preclinical (animal)
Sample size
not extracted
Randomization
no
Blinding
not stated
Comparator
not stated
Follow up duration
not stated
Outcome type
unknown
Replication
not assessed (auto)
Consistency with other evidence
not assessed (auto)
Population applicability
VERY_INDIRECT
Statistical precision
not extracted
Risk of bias
not assessed (auto)
Funding conflicts
unclear
Peer review status
no
02Funding

Funding and conflicts

Funding
not reported in abstract
Industry funded
Unclear
Manufacturer
None identified
Sponsor role
not reported in abstract
Author conflicts
not available in metadata
Independent replication
unknown

Funding is shown on every study and never used to score it.

04Source

The source, as retrieved

Abstract

Palatability and metabolic state strongly shape food consumption, making it important to understand the neural mechanisms that integrate these influences. Glucagon-like peptide-1 (GLP-1) receptor agonists are potent modulators of food intake and increasingly used therapeutic options, yet the circuit mechanisms underlying their effects remain unclear. Dorsal striatal inhibitory circuits contribute to reward-guided behavior and feeding, but how they encode ongoing consumption or are altered by GLP-1 receptor agonism is unknown. Using fiber photometry in mice, we found that dorsomedial striatal (DMS) GABA signals decreased at consumption onset, scaled with palatability, predicted licking, and were enhanced by food deprivation. GLP-1 receptor agonist semaglutide reduced intake, disrupted coupling between DMS GABA and licking, enhanced rebound signals preceding pauses, and increased DMS ensemble synchrony. Optogenetic excitation of DMS GABAergic interneurons reproduced key semaglutide-induced changes in consumption structure. These findings suggest that DMS GABA dynamics, as a state-dependent regulator of palatable consumption, are reshaped by GLP-1 receptor agonism.

Where this record came from

SourceRetrievedIdentifier
medrxiv:biorxivSep 20, 202610.64898/2026.09.03.749293
first ingestion